Oppenheimer & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Oppenheimer & Co’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-50,000	Closed	-$190K	–	1336
2020 Q1	$190K	Hold	50,000	–	–	0.01%	1042
2019 Q4	$255K	Hold	50,000	–	–	0.01%	1082
2019 Q3	$253K	Hold	50,000	–	–	0.01%	1044
2019 Q2	$309K	Buy	+50,000	New	+$241K	0.01%	994

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Oppenheimer & Co's PGNX Position: Q2 2020 in Review

Oppenheimer & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 50,000 shares — an estimated $190K sold.

Oppenheimer & Co first reported a position in PGNX in Q2 2019 and held it in 4 quarters. The position peaked at $309K in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Oppenheimer & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Oppenheimer & Co sold 50,000 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $190K.
Oppenheimer & Co first reported a position in Progenics Pharmaceuticals Inc in Q2 2019 and held it in 4 quarters.
Oppenheimer & Co's Progenics Pharmaceuticals Inc position peaked at $309K in Q2 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Oppenheimer & Co's 13F filing for Q2 2020, filed 11 Aug 2020.